Oncopeptides Pepaxti gets Marketing Authorization by MHRA in UK
Oncopeptides AB, a biotech company focused on R&D of development of therapies to treat haematological diseases, announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Pepaxti in combination with dexamethasone in the United Kingdom. The approval of Pepaxti in the United Kingdom is an important milestone for the […]
Continue Reading